Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 1040-1050

  Takahashi, Hidenori ^a   Ohigashi, Hiroaki ^a   Gotoh, Kunihito ^a   Marubashi, Shigeru ^a   Yamada, Terumasa ^a   Murata, Masayuki ^b   Ioka, Tatsuya ^b   Uehara, Hiroyuki ^a   Yano, Masahiko ^a   Ishikawa, Osamu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Department of Diagnostic Radiology ^*  (Japan)

Author keywords

borderline resectable; chemoradiation therapy; pancreatic cancer; preoperative treatment; resectable

Indexed keywords

GEMCITABINE;

AGED; ARTICLE; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER INCIDENCE; CANCER PATIENT; CHEMORADIOTHERAPY; DISTANT METASTASIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOPOIETIC TOXICITY; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANCREAS CANCER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RESECTABLE PANCREATIC CANCER; SURVIVAL RATE; TOXICITY; TREATMENT FAILURE;

AGED; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; PROSPECTIVE STUDIES;

EID: 84888129647     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31829b3ce4     Document Type: Article

References (45)

1. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210; discussion 1210-1211.
2. Sobin L,Gospodarowicz M,Wittekind C, eds.TNMClassification ofMalignant Tumors. 7th ed. New York, NY: Wiley-Liss; 2009.
3. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727-1733.
4. McClaine RJ, Lowy AM, Sussman JJ, et al. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2010;12:73-79.
5. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011;104:155-161.
6. NCCN GuidelinesR-. Pancreatic Adenocarcinoma. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed June 15, 2013.
7. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-1046.
8. Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2832-2838.
9. Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195:318-321.
10. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-846; discussion 846-848.
11. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18:619-627.
12. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
13. EvansDB,VaradhacharyGR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
14. Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88-95.
15. Talamonti MS, Small W, Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158.
16. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495.
17. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214-221.
18. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473.
19. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and metaanalysis of response and resection percentages. PLoS Med. 2010;7:e1000267.
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
22. Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg. 1988;208:215-220.
23. Takahashi H, Ohigashi H, Ishikawa O, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102.
24. Verbeke CS. Resection margins and R1 rates in pancreatic cancer-are we there yet? Histopathology. 2008;52:787-796.
25. Cancer Protocols and Checklists: College of American Pathologists-CAP Home. Protocol for the Examination of Specimens from Patients with Carcinoma of the Exocrine Pancreas. Available at: http://www.cap.org/apps/docs/committees/ cancer/cancer-protocols/2009/PancreasExo-09protocol.pdf. Accessed June 15, 2013.
26. Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. Chicago, IL: American Joint Committee on Cancer; 2010.
27. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
28. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed June 15, 2013.
29. Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615-621.
30. Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009;18:335-348.
31. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8-13.
32. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761-768.
33. Takahashi H, Ohigashi H, Ishikawa O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg. 2010;251:461-469.
34. Tse RV, Dawson LA, Wei A, et al. Neoadjuvant treatment for pancreatic cancer-a review. Crit Rev Oncol Hematol. 2008;65:263-274.
35. Le Scodan R, Mornex F, Partensky C, et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. Am J Clin Oncol. 2008;31: 545-552.
36. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;60:437-443.
37. Katz MH, Varadhachary GR, Fleming JB, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801.
38. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators [published online ahead of printMay 17, 2012]. Cancer. 2012;118:5749-5756. doi:10.1002/cncr.27636.
39. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabinebased chemoradiotherapy regimens in pancreatic cancer. Cancer. 2002;95 (4 suppl):933-940.
40. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
41. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
42. Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 1992;215:231-236.
43. Katz MH, Pisters PW, Lee JE, et al. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol. 2011;18:608-610.
44. Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255:103-108.
45. Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol. 2010;17:2803-2805.